1. Scrip
  2. >>Focus On Asia
  3. >>China

Kelun Highlights First-Line Plans For Merck-Partnered Trop2 ADC

 
• By Dexter Jie Yan

To differentiate from Daiichi Sankyo/AstraZeneca's Dato-DXd, Kelun and Merck & Co. are targeting the first-line treatment of EGFR wild-type NSCLC with a combination of their antibody-drug conjugate SKB-264 (MK-2870) with an anti-PD-1 antibody. Additionally, Kelun as the sole sponsor is advancing a Phase III study of the ADC as a monotherapy for second-line EGFR inhibitor-failed NSCLC.

first line treatment
1L treatment of EGFR-wild type NSCLC takes center stage in Kelun/Merck's plan for Trop2-targeting ADC • Source: Shutterstock

China's Sichuan Kelun Pharmaceutical Co Ltd. has stressed a first-line-focused clinical development strategy for its Merck & Co., Inc.-partnered trophoblast antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) SKB-264 (MK-2870) in epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer (NSCLC), in an effort to differentiate it from AstraZeneca PLC/Daiichi Sankyo Co., Ltd.'s datopotamab deruxtecan (Dato-DXd, DS1062), which works on the same target.

Shenzhen-listed Kelun made fresh overtures on the asset to a number of Chinese institutional investors on 5 July, after AstraZeneca had two days earlier announced disappointing early efficacy data for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Strong Data For CARsgen’s CAR-T In Late-Line Gastric Cancer

 
• By Dexter Jie Yan

In first confirmatory randomized controlled trial of any CAR-T therapy in solid tumors, CARsgen’s Claudin 18.2-targeting satri-cel reduced risk of death or disease progression by 63% in Chinese patients with gastric/gastroesophageal junction cancer.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

More from Focus On Asia

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.